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 BACKGROUND:  Pulmonary arterial hypertension (PAH) is a rare, severe disease characterized 
by worsening right-sided heart failure, decreasing functional status, and poor survival. Th e 
present study characterizes the 5-year survival in the United States of a new and previous diag-
nosis of PAH in patients stratifi ed by baseline functional class (FC). Th e Registry to Evaluate 
Early and Long-term PAH Disease Management (REVEAL Registry) is a 55-center observa-
tional US registry of the demographics, disease course, and management of patients with 
World Health Organization (WHO) group 1 PAH. 
 METHODS:  The REVEAL Registry enrolled newly and previously diagnosed patients 
aged   3 months with WHO group 1 PAH consecutively from March 2006 to December 2009. 
Demographics, disease characteristics, and hemodynamic data were collected at enrollment. 
Survival analysis was conducted by FC and other subgroups in patients aged   18 years. 
 RESULTS:  Survival diff erences between previously diagnosed and newly diagnosed patients at 
1 year (90.4% vs 86.3%) were maintained to 5 years; 5-year survival for previously diagnosed 
patients was 65.4% compared with 61.2% for newly diagnosed patients. Previously diagnosed 
patients in FC I, II, III, and IV had an estimated 5-year survival rate of 88.0%, 75.6%, 57.0%, 
and 27.2%, respectively, compared with 72.2%, 71.7%, 60.0%, and 43.8% for newly diagnosed 
patients in FC I, II, III, and IV, respectively. 
 CONCLUSIONS:  Patient survival of advanced PAH remains poor at 5 years despite treatment 
advances. New York Heart Association FC remains one of the most important predictors of 
future survival. Th ese observations reinforce the importance of continuous monitoring of FC 
in patients with PAH. 
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 ABBREVIATIONS:  6MWD  5 6-min walk distance; APAH-CHD  5 pulmo-
nary arterial hypertension associated with congenital heart disease includ-
ing both repaired and unrepaired; FC  5 functional class; FPAH  5 familial 
pulmonary arterial hypertension; IPAH  5 idiopathic pulmonary arterial 
hypertension; mPAP  5 mean pulmonary arterial pressure; mRAP  5 
mean right atrial pressure; PAH  5 pulmonary arterial hypertension; 
PCWP  5 pulmonary capillary wedge pressure; PVR  5 pulmonary 
vascular resistance; REVEAL Registry  5 Registry to Evaluate Early 
and Long-term PAH Disease Management; WHO  5 World Health 
Organization 
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 Pulmonary arterial hypertension (PAH) is a rare, severe 
disease characterized by worsening right-sided heart 
failure, decreasing functional status, and poor survival. 1 
Outcome evaluation by functional class (FC) is a key 
variable in many predictive models of PAH. Because 
either improvement or decline of FC over time signifi -
cantly predicts patient survival, 2 attainment of FC I or II 
is a critical treatment goal in practice and clinical trials. 2-4 
 Although the association between FC and survival is 
well established, limited survival estimates exist in the 
literature for FC subgroups. Additionally, most available 
data have evaluated survival to 3 years and are based on 
site cohort studies. 2,5,6 Previous studies examining sur-
vival data based on FC have a small sample size and do 
not refl ect current treatment strategies. 2,5-8 To date, there 
has been no multicenter, long-term analysis of survival 
by FC from a large cohort of patients with PAH. 
 Th e Registry to Evaluate Early and Long-term PAH 
Disease Management (REVEAL Registry) is an observa-
tional US disease registry providing current information 
about demographics, disease course, and management 
of patients with World Health Organization (WHO) 
group 1 PAH. Previous REVEAL Registry subset 
analyses demonstrate change in patient status, such as 
improvement from FC III to FC I/II or worsening from 
FC III to FC IV predicts signifi cantly better or worse 
survival, respectively, than if the patient remained at 
FC III. 9 Th e present REVEAL Registry analysis charac-
terizes 5-year survival of newly and previously diagnosed 
PAH in patients stratifi ed by baseline FC and provides 
survival estimates for a range of commonly examined 
PAH subsets, emphasizing simple, descriptive data rather 
than advanced modeling. Th ese data not only inform 
future clinical trial design but also increase awareness of 
the current burden at diff erent stages of this illness. 
 Materials and Methods 
 Th e REVEAL Registry design has been described previously. 10 Briefl y, 
the multicenter, observational, prospective registry enrolled patients 
aged   3 months with WHO group 1 PAH at 55 centers across the 
United States from March 2006 through December 2009. 10 Th e study was 
conducted in accordance with the amended Declaration of Helsinki, 
and the protocol was reviewed by the institutional review board of each 
participating center, with written informed consent obtained from all 
patients ( e-Table 1 ). 10 PAH was confi rmed by hemodynamic parameters 
using the Venice 2003 definition 11 and included mean pulmonary 
arterial pressure (mPAP)   25 mm Hg at rest or mPAP   30 mm Hg 
with exercise contemporaneously with pulmonary capillary wedge 
pressure (PCWP) or left  ventricular end-diastolic pressure  , 18 mm Hg 
and pulmonary vascular resistance (PVR)   240 dyn/s/cm 5 . 
 Th is analysis included patients aged   18 years, previously or newly 
diagnosed with WHO group 1 PAH (confi rmed by right-sided heart 
catheterization  . 90 days before enrollment or within 90 days, respec-
tively), with mPAP   25 mm Hg and PCWP   15 mm Hg measured at 
rest ( Fig 1 ). Patients with elevated PCWP ( . 15 mm Hg) or who met 
entry criteria only during exercise and patients initially included in 
the 2003 definition of WHO group 1 PAH 11 who are now part of 
group 1 9 12 were excluded. Patients were classifi ed as having idiopathic 
PAH (IPAH), familial PAH (FPAH), PAH associated with congeni-
tal heart disease (APAH-CHD) (repaired or, if unrepaired, with or 
without Eisenmenger syndrome), and/or PAH associated with con-
nective tissue disease (without signifi cant interstitial lung disease as 
defined by moderate or severe fibrosis on chest imaging or total 
lung capacity of 60% predicted) based on the 2003 PAH classifi cation 
scheme. 11 
 Data were summarized by descriptive statistics. Kaplan-Meier survival 
estimates   SE were calculated from the time of enrollment. Estimates 
were stratifi ed by previously and newly diagnosed PAH in patients and 
additional variables of interest. Kaplan-Meier curve comparisons were 
made on the basis of the log-rank test. 
 Primary survival analysis by FC was conducted for all patients with 
nonmissing FC data at enrollment ( Fig 1 ). FC changes were assessed 
in patients with a fi rst follow-up visit within 12 months aft er enroll-
ment. Th e overall population was assessed based on time of enrollment. 
Secondary survival analysis was conducted by subgroup, including 
previously or newly diagnosed, age, sex, race, PAH etiology, comor-
bidities (COPD, diabetes, BMI  . 30 kg/m 2 ), PAH clinical charac-
teristics at baseline (6-min walk distance [6MWD], brain natriuretic 
peptide level, REVEAL Registry risk score, 13,14 hemodynamics [mPAP, 
mean right atrial pressure (mRAP), PVR, cardiac index], and echo-
cardiographic fi ndings [pericardial eff usion and right ventricular dys-
function]). Patients with missing FC data at enrollment were included 
in secondary survival analyses of other subgroups. Th e fi nal February 
2013 REVEAL Registry data download was analyzed.  
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 Results 
 Patient Demographics and Clinical Characteristics 
 Th e primary analysis cohort included 2,039 previously 
diagnosed and 710 newly diagnosed patients who 
were not missing FC data at enrollment ( Fig 1 ). 
Demographics and clinical characteristics of each 
cohort according to FC are presented in  Tables 1 and 2 . 15 
Median time from diagnosis to enrollment was 32.2 
(interquartile range, 14.7-58.8) months for previously 
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 Figure 1 – STROBE (Strengthening the Reporting of Observational 
Studies in Epidemiology) diagram of patient inclusion and exclusion 
criteria. NYHA  5 New York Heart Association; PAH  5 pulmonary arte-
rial hypertension; PCWP  5 pulmonary capillary wedge pressure; 
REVEAL  5 Registry to Evaluate Early and Long-term PAH Disease 
Management; RHC  5 right-sided heart catheterization . 
diagnosed and 0.5 (interquartile range, 0.0-1.6) months 
for newly diagnosed patients, respectively. In total, 
1,085 previously diagnosed (53.2%) and 522 newly diag-
nosed (73.5%) patients were FC III or IV at enrollment. 
Although previously diagnosed patients in FC IV had a 
shorter 6MWD and higher mRAP at diagnosis than 
patients in other FCs, the mean cardiac index and mean 
PVR at diagnosis were similar across FC categories 
( Table 1 ). 
 Survival 
 Survival diff erences between previously diagnosed FC 
and newly diagnosed FC patients at 1 year (90.4%   
0.7% vs 86.3%   1.3%) were maintained to 5 years; 
5-year survival for previously diagnosed patients was 
65.4%   1.1% compared with 61.2%   2.0% for newly 
diagnosed patients ( P  5 .003 for the diff erence in sur-
vival times through 5 years) ( Fig 2 ,  e-Table 2 ). 
 Generally, compared with previously diagnosed 
patients, survival rates for newly diagnosed FC III 
and FC IV patients were numerically greater ( Figs 3, 4 , 
 e-Table 2 ). However, FC I and II survival rates were 
numerically lower in the newly diagnosed cohort. In 
pooled patients in FC I and II, previously diagnosed 
PAH was associated with signifi cantly better survival 
than newly diagnosed PAH (77.7%   1.4% vs 72.0%   
3.5%,  P  5 .010). FC was strongly associated with 5-year 
survival in specifi c etiologic groups. Previously diag-
nosed patients with IPAH or FPAH had estimated 
5-year survival rates of 85.7%   3.8%, 79.7%   2.1%, 
61.2%   2.3%, and 29.7%   7.8% for FC I, II, III, and IV, 
respectively ( Table 3 ). Newly diagnosed patients with 
IPAH or FPAH had estimated 5-year survival rates 
of 100%   0.0%, 74.9%   5.5%, 68.0%   3.5%, and 
52.9%   7.2% for FC I, II, III, and IV, respectively 
( Table 3 ). Estimated 5-year survival rates for previously 
diagnosed patients with APAH-CHD were 96.7%   
3.0%, 71.1%   3.7%, 43.9%   3.2%, and 15.8%   6.4% 
for FC I, II, III, and IV, respectively ( Table 3 ). Newly 
diagnosed patients with APAH-CHD had estimated 
5-year survival rates of 57.1%   18.7%, 64.6%   7.1%, 
44.5%   5.9%, and 19.8%   8.8% for FC I, II, III, and IV, 
respectively ( Table 3 ). 
 Changes in FC and Treatment Initiation 
 In total, 1,866 patients in the previously diagnosed cohort 
had an FC assessment at enrollment and a follow-up 
assessment within 12 months. Of the 889 patients 
classifi ed as FC III at enrollment, 173 (19%) improved 
to FC II within 12 months of enrollment; an addi-
tional 15 (2%) improved to FC I. Among patients in 
the newly diagnosed cohort with follow-up FC assess-
ments within 12 months of enrollment, 169 (27.5%) 
improved, 387 (63.0%) had no change, and 58 (9.5%) 
worsened by FC ( Table 4 ). When stratifi ed by FC at 
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enrollment, 370 newly diagnosed patients were classi-
fi ed as FC III, 100 (27%) improved to FC II within 
12 months of enrollment, and 12 (3%) improved to FC I. 
Among the 445 newly diagnosed patients in FC III or IV 
at baseline, 158 (35.5%) improved FC within 12 months 
of enrollment. 
 Patient status at enrollment aff ected treatment history 
and interventions. As expected, patients with more 
 TABLE 1  ]  Characteristics of Previously Diagnosed Patients a by FC at Enrollment (N  5 2,039) 
Characteristic All FCs b FC I FC II FC III FC IV
Demographic characteristics 
   at enrollment
 No. patients 2,039 162 792 991 94
 Age, y 51.7   14.5 47.0   14.2 49.3   14.4 54.1   14.1 55.9   14.9
 Aged  . 65 y 422 (20.7) 20 (12.3) 121 (15.3) 246 (24.8) 35 (37.2)
 Female sex 1,619 (79.4) 120 (74.1) 610 (77.0) 813 (82.0) 76 (80.9)
 Female:male ratio 3.9:1.0 2.9:1.0 3.4:1.0 4.6:1.0 4.2:1.0
Etiology of PAH at enrollment
 IPAH 950 (46.6) 83 (51.2) 367 (46.3) 462 (46.6) 38 (40.4)
 FPAH 64 (3.1) 7 (4.3) 27 (3.4) 29 (2.9) 1 (1.1)
 APAH-CTD 495 (24.3) 30 (18.5) 168 (21.2) 263 (26.5) 34 (36.2)
 APAH-CHD 236 (11.6) 11 (6.8) 97 (12.2) 120 (12.1) 8 (8.5)
 APAH-PoPH 110 (5.4) 13 (8.0) 45 (5.7) 48 (4.8) 4 (4.3)
 APAH-HIV 39 (1.9) 7 (4.3) 18 (2.3) 10 (1.0) 4 (4.3)
 APAH-drugs and toxins 121 (5.9) 9 (5.6) 58 (7.3) 51 (5.1) 3 (3.2)
Disease characteristics
  Most recent to enrollment c 
  6MWD, m 376   126 489   107 424   101 327   114 214   114
  FEV 1 , % predicted 76.6   18.1 83.2   17.1 79.0   16.9 74.3   18.5 70.1   19.0
  FVC, % predicted 80.8   17.9 78.9   16.7 83.2   16.8 78.5   18.2 73.6   19.7
  D LCO , % predicted 61.0   23.0 67.1   19.8 65.8   22.3 57.0   22.7 51.0   26.9
  At diagnosis
  mPAP, mm Hg 51.4   13.9 50.0   14.3 52.6   14.6 51.0   13.4 49.1   12.5
  mRAP, mm Hg 9.2   5.5 8.1   4.8 8.6   5.1 9.7   5.7 11.6   6.2
  CO, L/min 4.3   1.7 4.3   1.5 4.3   1.5 4.3   1.9 4.2   1.7
  Cardiac index, L/min/m 2 2.3   0.8 2.3   0.8 2.4   0.9 2.3   0.8 2.3   1.0
  PVR, Wood units 11.5   7.7 11.5   10.0 11.8   8.3 11.1   6.8 11.8   7.7
  PCWP, mm Hg 9.1   3.5 9.1   3.2 8.9   3.5 9.3   3.5 9.6   3.8
 Data are presented as mean   SD or No. (%). 6MWD  5 6-min walk distance; APAH-CHD  5 pulmonary arterial hypertension associated with congenital 
heart disease; APAH-CTD  5 pulmonary arterial hypertension associated with connective tissue disease including both repaired and unrepaired 
pulmonary arterial hypertension associated with congenital heart disease; APAH-drugs and toxins  5 pulmonary arterial hypertension associated with 
drugs and toxins; APAH-HIV  5 pulmonary arterial hypertension associated with HIV infection; APAH-PoPH  5 pulmonary arterial hypertension associated 
with portopulmonary hypertension; CO  5 cardiac output; D LCO  5 diﬀ using capacity of lung for carbon monoxide; FC  5 functional class; FPAH  5 familial 
pulmonary arterial hypertension; IPAH  5 idiopathic pulmonary arterial hypertension; mPAP  5 mean pulmonary arterial pressure; mRAP  5 mean right 
atrial pressure; PAH  5 pulmonary arterial hypertension; PCWP  5 pulmonary capillary wedge pressure; PVR  5 pulmonary vascular resistance. 
 a Previously diagnosed subjects are those whose diagnostic right-sided heart catheterization fell  . 90 d before enrollment. 
 b FC I: Patients with pulmonary hypertension but without resulting limitation of physical activity. Ordinary physical activity does not cause undue 
dyspnea or fatigue, chest pain, or near syncope. FC II: Patients with pulmonary hypertension resulting in slight limitation of physical activity. They 
are comfortable at rest. Ordinary physical activity causes undue dyspnea or fatigue, chest pain, or near syncope. FC III: Patients with pulmonary 
hypertension resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary activity causes undue dyspnea or 
fatigue, chest pain, or near syncope. FC IV: Patients with pulmonary hypertension with inability to carry out any physical activity without symptoms. 
These patients manifest signs of right-sided heart failure. Dyspnea, fatigue, or both may even be present at rest. Discomfort is increased by any 
physical activity. 
 c Because no assessments were mandated by protocol, the measurement at enrollment reﬂ ects the most recent assessment up to or including 
enrollment. Percent predicted FEV 1 and FVC values are based on Hankinson et al. 15 
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recent PAH diagnoses were more likely to initiate 
therapy than previously diagnosed patients. Only 
82 (4.0%) and 31 (1.5%) previously diagnosed patients 
received a fi rst PAH-specifi c therapy (endothelin 
receptor antagonists, phosphodiesterase-5 inhibitors, 
prostacyclin, or prostacyclin analogs) within 90 days 
before enrollment and 90 days aft er enrollment, respec-
tively ( Table 4 ). In contrast, 251 (35.4%) newly diag-
nosed patients received a fi rst PAH-specifi c therapy 
within 90 days before enrollment and 210 (29.6%) 
90 days aft er enrollment ( Table 4 ). 
 Survival Subgroup Analyses 
 Patient status and risk is commonly categorized by FC. 
However, because risk in PAH is multifactorial, 16 other 
potential variables were considered. Th ese secondary 
analyses included patients with missing FC categorization. 
Th e analysis set included 2,224 previously diagnosed 
 TABLE 2  ]  Characteristics of Newly Diagnosed Patients a by FC at Enrollment (N  5 710) 
Characteristic All FCs b FC I FC II FC III FC IV
Demographic characteristics 
   at enrollment
 No. patients 710 27 161 426 96
 Age, y 53.1   15.4 51.5   16.5 51.2   15.5 53.4   15.2 55.6   15.6
 Aged  . 65 y 170 (23.9) 6 (22.2) 34 (21.1) 100 (23.5) 30 (31.3)
 Female sex 552 (77.7) 19 (70.4) 127 (78.9) 331 (77.7) 75 (78.1)
 Female:male ratio 3.5:1.0 2.4:1.0 3.7:1.0 3.5:1.0 3.6:1.0
Etiology of PAH at enrollment
 IPAH 340 (47.9) 9 (33.3) 65 (40.4) 207 (48.6) 59 (61.5)
 FPAH 14 (2.0) 0 (0.0) 3 (1.9) 8 (1.9) 3 (3.1)
 APAH-CTD 218 (30.7) 9 (33.3) 58 (36.0) 129 (30.3) 22 (22.9)
 APAH-CHD 39 (5.5) 3 (11.1) 12 (7.5) 20 (4.7) 4 (4.2)
 APAH-PoPH 44 (6.2) 3 (11.1) 9 (5.6) 27 (6.3) 5 (5.2)
 APAH-HIV 12 (1.7) 1 (3.7) 2 (1.2) 8 (1.9) 1 (1.0)
 APAH-drugs and toxins 37 (5.2) 2 (7.4) 9 (5.6) 24 (5.6) 2 (2.1)
Disease characteristics
  Most recent to enrollment c 
  6MWD, m 310   126 367   134 394   105 291   113 221   130
  FEV 1 , % predicted 73.7   19.5 81.1   12.1 79.3   19.2 71.8   20.1 71.7   16.8
  FVC, % predicted 78.0   20.3 86.9   12.3 84.4   18.9 75.0   20.5 79.2   19.9
  D LCO , % predicted 50.9   21.5 51.8   23.1 56.3   24.0 49.5   20.3 48.5   21.7
  At diagnosis
  mPAP, mm Hg 50.1   12.9 44.3   10.8 46.8   12.0 50.6   13.1 55.4   11.6
  mRAP, mm Hg 10.0   6.0 6.3   4.6 9.1   5.8 9.9   5.7 12.8   7.3
  CO, L/min 4.2   1.4 4.6   1.5 4.4   1.5 4.2   1.4 3.6   1.1
  Cardiac index, L/min/m 2 2.2   0.7 2.5   0.8 2.3   0.8 2.2   0.8 1.9   0.6
  PVR, Wood units 11.2   6.0 9.1   6.0 9.9   5.3 11.3   6.1 14.1   5.6
  PCWP, mm Hg 9.3   3.6 8.2   4.0 9.0   3.7 9.4   3.5 10.2   3.5
 Data are presented as mean   SD or No. (%). See  Table 1 legend for expansion of abbreviations. 
 a Newly diagnosed subjects are those whose diagnostic right-sided heart catheterization fell within 90 d before enrollment. 
 b FC I: Patients with pulmonary hypertension but without resulting limitation of physical activity. Ordinary physical activity does not cause undue 
dyspnea or fatigue, chest pain, or near syncope. FC II: Patients with pulmonary hypertension resulting in slight limitation of physical activity. They 
are comfortable at rest. Ordinary physical activity causes undue dyspnea or fatigue, chest pain, or near syncope. FC III: Patients with pulmonary 
hypertension resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary activity causes undue dyspnea or 
fatigue, chest pain, or near syncope. FC IV: Patients with pulmonary hypertension with inability to carry out any physical activity without symptoms. 
These patients manifest signs of right-sided heart failure. Dyspnea, fatigue, or both may even be present at rest. Discomfort is increased by any 
physical activity. 
 c Because no assessments were mandated by protocol, the measurement at enrollment reﬂ ects the most recent assessment up to or including 
enrollment. Percent predicted FEV 1 and FVC values are based on Hankinson et al. 15 
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patients and 830 newly diagnosed patients ( Table 3 ). As 
expected, known risk factors, including baseline 6MWD, 
mRAP, and brain natriuretic peptide, were associated 
with survival ( Table 3 ). Compared with other races 
or ethnicities, white patients, previously or newly 
diagnosed, have relatively poor 5-year survival rates 
(63.5%   1.2% and 57.4%   2.3%, respectively). 
PVR   5 Wood units was associated with greater survival. 
Among previously diagnosed patients, 405 had a 
PVR   5 Wood units and a 5-year survival of 73.9%   
2.3%; 797 had a PVR of 5 to 10 Wood units and a 5-year 
survival of 66.0%   1.8%. Among newly diagnosed patients, 
108 had a PVR   5 Wood units and a 5-year survival 
of 70.1%   4.9%; 292 had a PVR of 5 to 10 Wood units 
and a 5-year survival of 57.3%   3.2%. Finally, in a 
potential instance of the obesity paradox, 17 higher 
 Figure 2 – Kaplan-Meier estimates 
of 5-y survival for previously diag-
nosed and newly diagnosed patients. 
dx  5 diagnosis. 
  
 Figure 3 – Kaplan-Meier estimates of 5-y survival for the subgroup of previously diagnosed patients, by FC at enrollment. FC I: Patients with pulmonary 
hypertension but without resulting limitation of physical activity. Ordinary physical activity does not cause undue dyspnea or fatigue, chest pain, or near 
syncope. FC II: Patients with pulmonary hypertension resulting in slight limitation of physical activity. Th ey are comfortable at rest. Ordinary physical 
activity causes undue dyspnea or fatigue, chest pain, or near syncope. FC III: Patients with pulmonary hypertension resulting in marked limitation of 
physical activity. Th ey are comfortable at rest. Less than ordinary activity causes undue dyspnea or fatigue, chest pain, or near syncope. FC IV: Patients 
with pulmonary hypertension with inability to carry out any physical activity without symptoms. Th ese patients manifest signs of right-sided heart fail-
ure. Dyspnea, fatigue, or both may even be present at rest. Discomfort is increased by any physical activity. FC  5 functional class. 
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BMI was associated with improved survival; 1,453 pre-
viously diagnosed patients with BMI   30 kg/m 2 and 
477 newly diagnosed patients had estimated survival 
rates of 64.6%   1.3% and 58.3%   2.5%, respectively; 
658 previously diagnosed patients with BMI  . 30 kg/m 2 
and 289 newly diagnosed patients had estimated sur-
vival rates of 69.6%   1.9% and 69.6%   2.9%, respec-
tively ( Table 3 ). 
 Discussion 
 Th is REVEAL Registry analysis demonstrates that 
5-year survival remains poor despite progress in 
PAH-specifi c therapy options and improved patient 
support strategies. Survival rates in previously diagnosed 
patients with PAH at 1, 3, and 5 years were 90.4%, 
76.2%, and 65.4%, respectively; in newly diagnosed 
patients, survival rates were 86.3%, 69.3%, and 61.2%, 
respectively ( e-Table 2 ). Prior to the development of 
PAH-specifi c therapies, median survival aft er diagnosis 
of IPAH (formerly primary pulmonary hypertension) 
was 2.8 years, with survival rates of 68%, 48%, and 
34% at 1, 3, and 5 years, respectively. 7 Furthermore, the 
present analysis shows that the prognosis for patients 
with advanced disease remains poor. 
 Th e poorest outcome was observed among patients in 
FC III or IV in both previously and newly diagnosed 
cohorts, with 5-year survival rates of 57.0% and 27.2%, 
and 60.0% and 43.8%, respectively. In addition to baseline 
FC status, FC change with treatment impacts patient 
outcome. A large number of newly diagnosed FC III 
and IV patients improved one FC within 12 months of 
enrollment. A previous REVEAL Registry analysis dem-
onstrated that improvement from FC III to FC I/II is 
associated with signifi cantly better survival than had the 
patient remained in FC III or worsened to FC IV. 9 Pre-
viously diagnosed patients classifi ed as FC IV at enroll-
ment have prior PAH-specifi c therapy exposure and 
fewer therapeutic options and may, thus, represent a 
cohort of patients nonresponsive or less responsive to 
therapy. In contrast, newly diagnosed patients classifi ed 
as FC IV at enrollment represent a treatment-naive 
population with a greater opportunity to improve with 
PAH-specifi c therapy. 18 Th is analysis demonstrates single 
point-in-time measurement of FC remains among the 
most important predictors of future survival in patients 
with PAH, despite its limitations. Th e current study 
includes a large cohort size, allowing various subgroup 
analyses and more detailed data on FC and FC changes 
during the enrollment period. 
 In addition to FC and disease duration before enroll-
ment, survival in patients with PAH was infl uenced by 
other clinical factors. Compared with the previously 
  
 Figure 4 – Kaplan-Meier estimates of 5-y survival for the subgroup of newly diagnosed patients, by FC at enrollment. FC I: Patients with pulmonary 
hypertension but without resulting limitation of physical activity. Ordinary physical activity does not cause undue dyspnea or fatigue, chest pain, or near 
syncope. FC II: Patients with pulmonary hypertension resulting in slight limitation of physical activity. Th ey are comfortable at rest. Ordinary physical 
activity causes undue dyspnea or fatigue, chest pain, or near syncope. FC III: Patients with pulmonary hypertension resulting in marked limitation of 
physical activity. Th ey are comfortable at rest. Less than ordinary activity causes undue dyspnea or fatigue, chest pain, or near syncope. FC IV: Patients 
with pulmonary hypertension with inability to carry out any physical activity without symptoms. Th ese patients manifest signs of right-sided heart 
failure. Dyspnea, fatigue, or both may even be present at rest. Discomfort is increased by any physical activity. See  Figure 3 legend for expansion of 
abbreviation. 
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 TABLE 3  ]  K-M Estimates of 5-Year Survival by Previously vs Newly Diagnosed Patients a 
Previously Diagnosed Newly Diagnosed
Characteristic No. 5-y K-M   SE, % No. 5-y K-M   SE, %
Age at enrollment, y
 18-34 305 78.8   2.5 110 78.5   4.0
 35-54 951 71.5   1.5 312 70.7   2.8
 55-64 503 60.7   2.3 199 52.4   4.0
   65 465 49.2   2.4 209 42.8   4.2
Sex
 Male 456 57.4   2.4 188 53.0   4.0
 Female 1,768 67.5   1.2 642 62.9   2.1
Race/ethnicity
 White 1,618 63.5   1.2 588 57.4   2.3
 Black 274 67.7   3.0 120 66.0   4.6
 Hispanic 201 73.2   3.3 65 67.6   6.0
 Other 131 71.4   4.2 57 74.7   5.9
Etiology of PAH at enrollment b 
 IPAH 1,027 69.4   1.5 399 68.0   2.5
 FPAH 64 65.8   6.1 19 73.7   10.1
 APAH-CTD 556 55.8   2.2 254 47.6   3.8
  SSc 339 46.2   2.8 165 39.6   4.7
  Non-SSc 217 71.3   3.2 89 63.3   5.8
 APAH-CHD 262 70.0   2.9 40 73.9   7.1
 APAH-PoPH 122 49.6   4.7 55 34.3   6.8
 APAH-HIV 40 73.8   7.1 14 73.0   14.0
 APAH-drugs and toxins 124 76.9   3.9 40 74.9   7.6
Etiology of PAH by FC, both at enrollment
 IPAH/FPAH
  FC I 90 85.7   3.8 9 100   0.0
  FC II 394 79.7   2.1 68 74.9   5.5
  FC III 491 61.2   2.3 215 68.0   3.5
  FC IV 39 29.7   7.8 62 52.9   7.2
 APAH-CHD
  FC I 11 96.7   3.0 3 57.1   18.7
  FC II 97 71.1   3.7 12 64.6   7.1
  FC III 120 43.9   3.2 20 44.5   5.9
  FC IV 8 15.8   6.4 4 19.8   8.8
Comorbidities at enrollment
 Diabetes
  Yes 249 53.5   3.3 112 46.0   5.0
  No 1,932 67.0   1.1 690 63.5   2.0
 COPD
  Yes 190 49.9   3.8 114 46.8   5.0
  No 1,991 66.9   1.1 688 63.4   2.0
 BMI  . 30 kg/m 2 
(Continued)
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Previously Diagnosed Newly Diagnosed
Characteristic No. 5-y K-M   SE, % No. 5-y K-M   SE, %
  Yes 658 69.6   1.9 289 69.6   2.9
  No 1,453 64.6   1.3 477 58.3   2.5
Disease characteristics at enrollment b 
 6MWD, m
   , 165 121 28.7   4.4 83 35.7   5.9
  165 to  , 440 1,184 63.8   1.5 361 65.4   2.8
    440 547 81.9   1.7 81 83.8   4.8
 BNP, pg/mL
   . 180 414 41.3   2.5 193 46.8   4.0
  50-180 342 67.1   2.7 94 74.1   4.7
   , 50 334 85.5   2.0 53 92.3   3.7
REVEAL Registry risk score at enrollment
 1-7 1,211 80.9   1.2 284 80.9   2.6
 8 363 62.9   2.7 153 69.2   4.0
 9 273 51.1   3.3 150 58.9   4.4
 10-11 302 29.6   2.8 176 34.3   4.5
   12 75 12.3   4.0 67 29.8   5.8
Hemodynamics at enrollment b 
 mPAP, mm Hg (at rest)
   , 50 1,146 66.8   1.5 427 60.5   2.7
    50 1,010 63.9   1.6 363 60.9   2.7
 Cardiac index, L/min/m 2 
    2 1,289 69.1   1.3 386 62.1   2.8
   , 2 478 59.6   2.3 265 58.6   3.3
 mRAP, mm Hg
   , 10 1,278 70.6   1.3 394 64.1   2.7
  10-14 458 62.8   2.3 192 55.2   3.9
    15 280 47.4   3.1 134 54.3   4.6
 PVR, Wood units
    5 405 73.9   2.3 108 70.1   4.9
  5-10 797 66.0   1.8 292 57.3   3.2
   , 10 1,202 68.7   1.4 400 60.7   2.7
  10-16 586 60.3   2.1 262 63.2   3.2
    17 225 59.8   3.4 119 56.9   4.9
Echocardiographic ﬁ ndings at enrollment b 
 Pericardial eﬀ usion c 
  Yes 437 50.8   2.5 179 58.4   4.0
  No 1,312 69.9   1.3 389 59.9   2.7
 Right ventricular dysfunction d 
  Yes 814 57.2   1.8 363 59.2   2.9
  No 927 72.9   1.5 214 60.4   3.6
TABLE 3 ] (continued)
(Continued)
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Previously Diagnosed Newly Diagnosed
Characteristic No. 5-y K-M   SE, % No. 5-y K-M   SE, %
Lung function at enrollment
 FEV 1 , e % predicted
   , 80% 813 60.0   1.8 289 51.5   3.4
    80% 615 71.2   1.9 171 66.8   4.0
 FVC, e % predicted
   , 80% 684 57.9   1.9 250 52.4   3.5
    80% 749 71.0   1.7 215 63.4   3.7
 D LCO , % predicted
   , 80% 1,065 63.2   1.5 389 53.8   2.8
    80% 269 74.8   2.8 55 84.6   5.5
 BNP  5 brain natriuretic peptide; K-M  5 Kaplan-Meier; REVEAL Registry  5 Registry to Evaluate Early and Long-term PAH Disease Management; 
SSc  5 systemic sclerosis. See  Table 1 legend for expansion of other abbreviations. 
 a Newly diagnosed subjects are those whose diagnostic right-sided heart catheterization fell within 90 d before enrollment. Previously diagnosed 
subjects are those whose diagnostic right-sided heart catheterization fell  . 90 d before enrollment. 
 b Because no assessments were mandated by protocol, the measurement at enrollment reﬂ ects the most recent assessment up to or including 
enrollment. 
 c Mild, moderate, moderate-severe, and severe are categorized as yes; none is categorized as no. 
 d Moderate, moderate-severe, and severe are categorized as yes; mild and none are categorized as no. 
 e Percent predicted values are based on Hankinson et al. 15 
TABLE 3 ] (continued)
diagnosed patients, Kaplan-Meier survival estimates of 
newly diagnosed patients demonstrated early decreases 
in survival. Th e present newly diagnosed patient cohort 
includes substantially more patients in FC III and IV 
(74% vs 53%). Th e highest mortality risk in patients 
with PAH may present at the time of diagnosis and 
before treatment initiation. 5,8 Th e data support a diff er-
ence in risk profi les for previously vs newly diagnosed 
patients and a high, immediate risk in newly diagnosed 
patients. 
 Of note, survival analysis in PAH cohorts are prone to 
survivor bias 19 when patients with diff erent disease 
durations are pooled. Under these conditions, survival 
estimates for the overall cohort are more favorable than 
if the survival estimate is derived using newly diagnosed 
patients only, since prevalent patients have a better 
prognosis than incident or newly diagnosed patients. 5,13 
Previously and newly diagnosed patients have diff erent 
risk profi les because many higher-risk patients do not 
survive for a suffi  cient duration to be enrolled as previ-
ously diagnosed patients. Th us, the previously diag-
nosed cohort will always contain a smaller percentage of 
patients in FC IV compared with the newly diagnosed 
cohort. Th e persistence of survivor bias aft er adjustment 
for risk profi le diff erences has not been established. 
 Here, the survival disadvantage of newly diagnosed 
patients is most pronounced among patients in FC I and II, 
suggesting a relatively favorable risk profile at diagno-
sis reflects an earlier diagnosis but does not neces-
sarily guarantee a good outcome. Conversely, any 
survival advantage associated with a previous diagnosis 
is absent for patients in FC III and IV. Previously diag-
nosed patients who remain short of treatment goals 
(eg, FC III) likely have less potential for future improve-
ment, but a negative outcome is not inevitable. 
Improvement in a high percentage of patients in newly 
diagnosed FC III is likely related to administration of 
initial PAH-specifi c therapy within 90 days before or 
90 days aft er enrollment, thus providing an opportunity 
to respond to treatment. In contrast, few previously diag-
nosed patients initiated fi rst PAH-specifi c therapy at 
enrollment, and a smaller percentage in the previously 
diagnosed FC III group at enrollment improved to FC II, 
suggesting an already maximized response. Although 
treatment decisions were left  to the contributing pro-
viders and were not mandated by REVEAL Registry, it 
is clear that patients experience greatest risk in the ini-
tial months aft er diagnosis. 20-23 Th us, treatment should 
be initiated as early as possible as newly diagnosed 
patients are at greatest risk and have the greatest oppor-
tunity to show functional improvements. FC assessment 
is remarkably predictive of survival in PAH; its use as a 
tool in clinical practice and trials should continue. 
 Th is analysis was hypothesis generating and, therefore, 
explored many variables. Trends of interest must be 
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 TABLE 4  ]  Timing of Diagnosis, First Medication Use, and Change in FC by Previously vs Newly Diagnosed 
Patients a 
Variable Previously Diagnosed (n  5 2,039) Newly Diagnosed (n  5 710)
Time from diagnosis to enrollment, mo
 Median (interquartile range) 32.2 (14.7-58.8) 0.5 (0.0-1.6)
 Mean   SD 44.4   44.5 0.8   1.3
Timing of ﬁ rst PAH-speciﬁ c medication b 
  . 90 d before enrollment 1,834 (89.9) 102 (14.4)
 1-90 d before enrollment 82 (4.0) 251 (35.4)
 Day of enrollment 11 (0.5) 62 (8.7)
 1-90 d after enrollment 31 (1.5) 210 (29.6)
  . 90 d after enrollment 34 (1.7) 48 (6.8)
 Never initiated c 47 (2.3) 37 (5.2)
FC change between diagnosis and enrollment, d 
  all patients
 Improved between diagnosis and enrollment 534 (35.0) 73 (11.1)
 No change between diagnosis and enrollment 845 (55.4) 557 (84.7)
 Worsened between diagnosis and enrollment 146 (9.6) 28 (4.3)
FC change between enrollment d and 12-mo update, 
  all patients
 Improved by 12-mo update 267 (14.3) 169 (27.5)
 No change by 12-mo update 1,378 (73.9) 387 (63.0)
 Worsened by 12-mo update 221 (11.8) 58 (9.5)
FC I or II at enrollment
 Improved by 12-mo update 43 (4.7) 11 (6.5)
 No change by 12-mo update 690 (76.0) 113 (66.9)
 Worsened by 12-mo update 175 (19.3) 45 (26.6)
FC III or IV at enrollment
 Improved by 12-mo update 224 (23.4) 158 (35.5)
 No change by 12-mo update 688 (71.8) 274 (61.6)
 Worsened by 12-mo update 46 (4.8) 13 (2.9)
 Data are presented as No. (%) unless otherwise indicated. See  Table 1 legend for expansion of abbreviations. 
 a Newly diagnosed subjects are those whose diagnostic right-sided heart catheterization fell within 90 d before enrollment. Previously diagnosed 
subjects are those whose diagnostic right-sided heart catheterization fell  . 90 d before enrollment. 
 b First initiation of an endothelin receptor antagonist, phosphodiesterase-5 inhibitor, prostacyclin, or prostacyclin analog. 
 c Thirty-nine of 84 patients initiated calcium channel blockers for PAH. 
 d Because no assessments were mandated by protocol, the measurement at enrollment reﬂ ects the most recent assessment up to or including enrollment. 
externally validated. Comparisons were not risk 
adjusted and stratifi ed only by diagnosis (previously 
vs newly); many diff erences may be explained by con-
founding factors. Although developments in treat-
ment may explain diff erences in the disease trajectory 
for previously and newly diagnosed patients, other 
factors also aff ect disease management. Upon new 
diagnosis, changes in patient care, access to health 
care, and lifestyle changes all affect treatment effi-
cacy. However, registries are not ideally designed to 
specifi cally address many of these issues. Moreover, 
because REVEAL Registry is a US-based cohort, gener-
alization of these observations to other countries is 
unknown. 
 Conclusions 
 Although overall survival for patients with WHO group 
1 PAH has greatly improved in the current treatment 
era, this analysis of the REVEAL Registry shows that 
patient prognosis remains poor. Relative to corre-
sponding previously diagnosed patients, newly diagnosed 
patients have a survival disadvantage. FC, whether with 
newly or previously diagnosed disease, is predictive of 
survival. Th ese data reinforce the importance of contin-
uous monitoring of FC in patients with PAH. 
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